BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch

Reuters09-05

** Brokerage Maxim upgrades women's health firm Daré Bioscience DARE.O to "buy" from "hold" with a price target of $8

** Brokerage expects upside from Daré's $17.6 million fundraise in July 2025 via the at-the-market program and a $6 million grant, saying the funds extend the runway into 2H26

** Brokerage sees the initial launch of topical sildenafil as a near-term catalyst and the launch is targeted for the fourth quarter of 2025

** Topical sildenafil is an experimental cream used to treat female sexual arousal disorder

** "While additional funding will likely be required, we view the upcoming launch as an important milestone that enhances visibility and validates the commercial opportunity" - brokerage

** Including session's move, DARE stock down 33.3% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2565309614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565309614","market":"nz","top_or_hot":-1,"title":"BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch</title></head><body><p>** Brokerage Maxim upgrades women's health firm Daré Bioscience <span>DARE.O</span> to \"buy\" from \"hold\" with a price target of $8</p><p>** Brokerage <span>expects</span> upside from Daré's $17.6 million fundraise in July 2025 via the at-the-market program and a $6 million grant, saying the funds extend the runway into 2H26</p><p>** Brokerage sees the initial launch of topical sildenafil as a near-term catalyst and the launch is targeted for the fourth quarter of 2025</p><p>** Topical sildenafil is an experimental cream used to treat female sexual arousal disorder    </p><p>** \"While additional funding will likely be required, we view the upcoming launch as an important milestone that enhances visibility and validates the commercial opportunity\" - brokerage</p><p>** Including session's move, DARE stock down 33.3% YTD </p><p>(Reporting by Padmanabhan Ananthan)</p><p>((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 00:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch</title></head><body><p>** Brokerage Maxim upgrades women's health firm Daré Bioscience <span>DARE.O</span> to \"buy\" from \"hold\" with a price target of $8</p><p>** Brokerage <span>expects</span> upside from Daré's $17.6 million fundraise in July 2025 via the at-the-market program and a $6 million grant, saying the funds extend the runway into 2H26</p><p>** Brokerage sees the initial launch of topical sildenafil as a near-term catalyst and the launch is targeted for the fourth quarter of 2025</p><p>** Topical sildenafil is an experimental cream used to treat female sexual arousal disorder    </p><p>** \"While additional funding will likely be required, we view the upcoming launch as an important milestone that enhances visibility and validates the commercial opportunity\" - brokerage</p><p>** Including session's move, DARE stock down 33.3% YTD </p><p>(Reporting by Padmanabhan Ananthan)</p><p>((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DARE","symbol_name":"Dare Bioscience","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nL6N3UR0SQ:1","article_id":"2565309614","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565309614","pubTimestamp":1757003557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch** Brokerage Maxim upgrades women's health firm Daré Bioscience DARE.O to \"buy\" from \"hold\" with a price target of $8** Br","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"DARE":"Dare Bioscience"},"translate_title":"BUZZ-Maxim升级DaréBioscience，延长现金跑道并进行商业发布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DARE":0.9},"content_text":"BUZZ-Maxim upgrades Daré Bioscience on extended cash runway, commercial launch** Brokerage Maxim upgrades women's health firm Daré Bioscience DARE.O to \"buy\" from \"hold\" with a price target of $8** Brokerage expects upside from Daré's $17.6 million fundraise in July 2025 via the at-the-market program and a $6 million grant, saying the funds extend the runway into 2H26** Brokerage sees the initial launch of topical sildenafil as a near-term catalyst and the launch is targeted for the fourth quarter of 2025** Topical sildenafil is an experimental cream used to treat female sexual arousal disorder    ** \"While additional funding will likely be required, we view the upcoming launch as an important milestone that enhances visibility and validates the commercial opportunity\" - brokerage** Including session's move, DARE stock down 33.3% YTD (Reporting by Padmanabhan Ananthan)((Padmanabhan.Ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565309614","isCrawlerRequest":true}